{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:51:52Z","timestamp":1794009112222,"version":"4.8.0"},"reference-count":30,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This study explored the combination of fibroblast activation protein (FAP) IL2 variant (FAP-IL2v), a novel immune-cytokine, with pembrolizumab in patients with advanced and\/or metastatic melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This open-label, multicenter, phase Ib clinical study (NCT03875079) evaluated the safety, tolerability, pharmacodynamics, pharmacokinetics, and antitumor activity of FAP-IL2v (simlukafusp alfa, RO6874281) in combination with pembrolizumab. Patients with advanced and\/or metastatic melanoma were either checkpoint inhibitor (CPI)-na\u00efve or CPI-experienced. Patients received 10 mg FAP-IL2v either continuously once every 3 weeks (Q3W) or in an induction\/maintenance setting consisting of a 3-week induction phase with weekly (QW) dosing followed by continuous Q3W dosing. Pembrolizumab was dosed Q3W at 200 mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Eighty-three patients were treated: 16 patients in two safety run-in cohorts and 67 patients in two extension cohorts; 75 (90.4%) patients were CPI-experienced. The pharmacokinetics of FAP-IL2v in combination with pembrolizumab was similar to that after administration as monotherapy. Consistent with the proposed mode of action, FAP-IL2v preferentially expanded NK and CD8 T cells. The most common FAP-IL2v\u2013related grade 3\/4 adverse events were lymphopenia (23%), elevated \u03b3-glutamyltransferase (8%), elevated alanine aminotransferase (6%), and infusion-related reaction (6%). A response was observed in 5 of 75 (6.7%) CPI-experienced patients (all partial responses) and 2 of 8 CPI-na\u00efve patients (one complete response and one partial response). The median progression-free survival was 3.1 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The safety profile of FAP-IL2v in combination with pembrolizumab was manageable and consistent with the known safety profile. However, further exploration of FAP-IL2v and pembrolizumab was precluded in patients with melanoma with prior CPI due to the lack of clinical activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In this phase Ib study, the combination of FAP-IL2v, an immune-cytokine developed to overcome the limitations of wild-type IL2, with the CPI pembrolizumab did not show meaningful antitumor activity in patients who had progressed on prior CPI therapy, suggesting that FAP-IL2v alone cannot overcome CPI resistance or unresponsiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0601","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T04:39:01Z","timestamp":1738557541000},"page":"358-368","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and\/or Metastatic Melanoma"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7556-7608","authenticated-orcid":false,"given":"Eva","family":"Munoz-Couselo","sequence":"first","affiliation":[{"name":"1Vall d\u2019Hebron University Hospital, VHIO, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-8989","authenticated-orcid":false,"given":"Ainara","family":"Soria Rivas","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, University Hospital Ram\u00f3n y Cajal, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-4475","authenticated-orcid":false,"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"4Melanoma Institute Australia, The University of Sydney, Sydney, Australia."},{"name":"5Faculty of Medicine and Health, The University of Sydney, Sydney, Australia."},{"name":"6Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7295-6074","authenticated-orcid":false,"given":"Miguel F.","family":"Sanmamed","sequence":"additional","affiliation":[{"name":"7Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain."},{"name":"8CIBERONC, Instituto de Salud Carlos III, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3034-3042","authenticated-orcid":false,"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[{"name":"9Division of Medical Oncology, Princess Margaret Cancer Centre University Health Network, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-8953","authenticated-orcid":false,"given":"Elizabeth","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"10Beth Israel Deaconess Medical Center, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-9662","authenticated-orcid":false,"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[{"name":"11Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-7352","authenticated-orcid":false,"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[{"name":"12Antwerp University Hospital, Edegem, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4927-5585","authenticated-orcid":false,"given":"Alexander","family":"Fedenko","sequence":"additional","affiliation":[{"name":"13P.A. Gertsen Moscow Oncology Research Institute, Moscow, Russia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-6824","authenticated-orcid":false,"given":"Mohammed","family":"Milhem","sequence":"additional","affiliation":[{"name":"14University of Iowa, Iowa City, Iowa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-1957","authenticated-orcid":false,"given":"Ana Maria","family":"Arance Fernandez","sequence":"additional","affiliation":[{"name":"15Department of Oncology, Hospital Cl\u00ednic of Barcelona and IDIBAPS, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-153X","authenticated-orcid":false,"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[{"name":"16APHM and Aix-Marseille University, Marseille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8562-6082","authenticated-orcid":false,"given":"Lev","family":"Demidov","sequence":"additional","affiliation":[{"name":"17N.N. Blokhin Russian Cancer Research Center, Moscow, Russia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-0238","authenticated-orcid":false,"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[{"name":"18Institut Gustave Roussy and Paris Saclay University, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5806-7650","authenticated-orcid":false,"given":"Christin","family":"Habigt","sequence":"additional","affiliation":[{"name":"19Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Munich, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3060-9429","authenticated-orcid":false,"given":"Stefan","family":"Evers","sequence":"additional","affiliation":[{"name":"20Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5705-0786","authenticated-orcid":false,"given":"Nassim","family":"Sleiman","sequence":"additional","affiliation":[{"name":"20Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8960-5345","authenticated-orcid":false,"given":"David","family":"Dejardin","sequence":"additional","affiliation":[{"name":"20Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9845-8307","authenticated-orcid":false,"given":"Caroline","family":"Ardeshir","sequence":"additional","affiliation":[{"name":"21F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1358-0739","authenticated-orcid":false,"given":"Nicole","family":"Martin","sequence":"additional","affiliation":[{"name":"22Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8467-0339","authenticated-orcid":false,"given":"Christophe","family":"Boetsch","sequence":"additional","affiliation":[{"name":"20Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5409-9160","authenticated-orcid":false,"given":"Jehad","family":"Charo","sequence":"additional","affiliation":[{"name":"22Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0526-6584","authenticated-orcid":false,"given":"Volker","family":"Teichgr\u00e4ber","sequence":"additional","affiliation":[{"name":"20Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5831-8054","authenticated-orcid":false,"given":"Anton","family":"Kraxner","sequence":"additional","affiliation":[{"name":"20Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0978-3393","authenticated-orcid":false,"given":"Nino","family":"Keshelava","sequence":"additional","affiliation":[{"name":"22Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0667-3284","authenticated-orcid":false,"given":"Oliver","family":"Bechter","sequence":"additional","affiliation":[{"name":"23Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium."},{"name":"24Department of Oncology, KU Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"2025022411000844600_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025022411000844600_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/OP.21.00686","article-title":"Managing metastatic melanoma in 2022: a clinical review","volume":"18","author":"Switzer","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2025022411000844600_bib3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/j.seminoncol.2015.05.015","article-title":"Anticancer cytokines: biology and clinical effects of interferon-\u03b12, interleukin (IL)-2, IL-15, IL-21, and IL-12","volume":"42","author":"Floros","year":"2015","journal-title":"Semin Oncol"},{"key":"2025022411000844600_bib4","doi-asserted-by":"crossref","first-page":"1913791","DOI":"10.1080\/19420862.2021.1913791","article-title":"Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy","volume":"13","author":"Waldhauer","year":"2021","journal-title":"MAbs"},{"key":"2025022411000844600_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4161\/cbt.13.3.18696","article-title":"Fibroblast activation protein: a potential therapeutic target in cancer","volume":"13","author":"Liu","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"2025022411000844600_bib6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteomics Clin Appl"},{"key":"2025022411000844600_bib7","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"2025022411000844600_bib8","doi-asserted-by":"crossref","first-page":"1352615","DOI":"10.3389\/fimmu.2024.1352615","article-title":"Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies","volume":"15","author":"Dziadek","year":"2024","journal-title":"Front Immunol"},{"key":"2025022411000844600_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1471-2407-11-245","article-title":"FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells","volume":"11","author":"Lee","year":"2011","journal-title":"BMC Cancer"},{"key":"2025022411000844600_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2217\/imt-2020-0066","article-title":"Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy","volume":"13","author":"Brennen","year":"2021","journal-title":"Immunotherapy"},{"key":"2025022411000844600_bib11","doi-asserted-by":"crossref","first-page":"1352632","DOI":"10.3389\/fimmu.2024.1352632","article-title":"Investigating the complex interplay between fibroblast activation protein \u03b1-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy","volume":"15","author":"Kraxner","year":"2024","journal-title":"Front Immunol"},{"key":"2025022411000844600_bib12","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/hmg\/ddae056","article-title":"Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies","volume":"33","author":"Zhou","year":"2024","journal-title":"Hum Mol Genet"},{"key":"2025022411000844600_bib13","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1158\/1078-0432.CCR-23-3567","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity from a phase I study of simlukafusp alfa (FAP-IL2v) in advanced\/metastatic solid tumors","volume":"30","author":"Steeghs","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025022411000844600_bib14","doi-asserted-by":"crossref","first-page":"105374","DOI":"10.1016\/j.ebiom.2024.105374","article-title":"Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and\/or metastatic cervical squamous cell carcinoma","volume":"109","author":"Verlingue","year":"2024","journal-title":"EBioMedicine"},{"key":"2025022411000844600_bib15","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1158\/1078-0432.CCR-23-2677","article-title":"Phase II study to determine the antitumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer","volume":"30","author":"Prenen","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025022411000844600_bib16","article-title":"Aldesleukin precribing information","author":"Laboratories","year":"2012"},{"key":"2025022411000844600_bib17","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1200\/JCO.2021.39.15_suppl.4556","article-title":"Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp \u03b1 in combination with atezolizumab \u00b1 bevacizumab in patients with unresectable advanced\/ metastatic renal cell carcinoma (RCC) (NCT03063762)","volume":"39","author":"Perez-Gracia","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025022411000844600_bib18","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti\u2013programmed death-1\/programmed death ligand 1 therapy: results from the phase I\/IIa RELATIVITY-020 trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025022411000844600_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.22.00221","article-title":"Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination","volume":"41","author":"Arance","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025022411000844600_bib20","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat Med"},{"key":"2025022411000844600_bib21","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025022411000844600_bib22","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/blood-2005-06-2399","article-title":"IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients","volume":"107","author":"Ahmadzadeh","year":"2006","journal-title":"Blood"},{"key":"2025022411000844600_bib23","doi-asserted-by":"crossref","first-page":"1233261","DOI":"10.3389\/fimmu.2023.1233261","article-title":"Cytotoxic CD4 T cells in the mucosa and in cancer","volume":"14","author":"Venkatesh","year":"2023","journal-title":"Front Immunol"},{"key":"2025022411000844600_bib24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s43018-021-00221-9","article-title":"Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma","volume":"2","author":"Haas","year":"2021","journal-title":"Nat Cancer"},{"key":"2025022411000844600_bib25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00403-022-02425-0","article-title":"An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: prognostic capabilities and demographic variability","volume":"315","author":"Desai","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2025022411000844600_bib26","doi-asserted-by":"crossref","first-page":"2197360","DOI":"10.1080\/2162402X.2023.2197360","article-title":"Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2R\u03b2\u03b3-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition","volume":"12","author":"Codarri Deak","year":"2023","journal-title":"Oncoimmunology"},{"key":"2025022411000844600_bib27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.immuni.2022.12.006","article-title":"Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages","volume":"56","author":"Tichet","year":"2023","journal-title":"Immunity"},{"key":"2025022411000844600_bib28","doi-asserted-by":"crossref","first-page":"A224.2","DOI":"10.1136\/jitc-2020-SITC2020.0368","article-title":"368 REVEAL: phase 1 dose-escalation study of NKTR-262, a novel TLR7\/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors","volume-title":"Regular and young investigator award abstracts","author":"Diab","year":"2020"},{"key":"2025022411000844600_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"key":"2025022411000844600_bib30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13000-023-01318-8","article-title":"Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring","volume":"18","author":"Liu","year":"2023","journal-title":"Diagn Pathol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0601\/3538580\/crc-24-0601.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/2\/358\/3546003\/crc-24-0601.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/2\/358\/3546003\/crc-24-0601.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:00:30Z","timestamp":1740376830000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/2\/358\/752055\/Phase-Ib-Study-of-Immunocytokine-Simlukafusp-Alfa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0601","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7687181","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.28471010","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28470980","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28470974","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28470995","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28471004","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28471007","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28470971","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28470989","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28470977","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28470998","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28470986","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}